You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The team will launch a Phase II study to validate early-stage gastric cancer micro-RNA biomarkers and eventually develop liquid biopsy tests.
The company recently presented results from its Aurora assay for multi-cancer screening and plans to launch a $100 test for the US and Chinese markets.
In PNAS this week: study of central nervous system inflammation roots, circulating immune cells in cancer reflect patient response to treatment, and more.
Investigators are building upon an initial case study that allowed them to assess how well ctDNA captured a cancer's full genomic heterogeneity compared to tissue biopsies.
In Science this week: mass spectrometric analysis of the SARS-CoV-2 spike protein, and more.
Alcohol use in combination with ALDH2 mutations or germline changes in the CDH1 gene corresponded to a subset of diffuse-type gastric cancer cases in East Asian individuals.
The companies are looking to model gene expression signatures to predict treatments for gastric cancer and improve patient stratification methodologies.
Palmetto has expanded the local coverage determination for the Guardant360 liquid biopsy assay to be used with the majority of advanced solid tumors.
The company's +RNAinsight test, a combined DNA and RNA genetic test for hereditary cancer syndromes, was launched in October.
The researchers estimated that addition of RNA-based testing could benefit about 1 in 43 individuals undergoing hereditary cancer predisposition genetic testing.
NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.
According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.
In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.
Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.